Sangamo Therapeutics stock analysis
Want to see SGMOQ full AI Analyst Report?
Sangamo Therapeutics (SGMOQ) Stock Price & Analysis
SGMOQ Stock Chart & Stats
- Day’s Range
- $0.11 - $0.12
- 52-Week Range
- $0.01 - $0.60
- Previous Close
- $0.12
- Volume
- N/A
- Average Volume (3M)
- 1.33M
- Market Cap
- $45.12M
- Enterprise Value
- $87.94M
- Total Cash (Recent Filing)
- $27.59M
- Total Debt (Recent Filing)
- $19.33M
- Price to Earnings (P/E)
- ―
- Beta
- 2.36
- Next Earnings
- Feb 24, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Genomic Medicine Focus
A focused genomic-medicine platform gives Sangamo exposure to therapies addressing serious diseases and preserves specialized scientific capabilities. Its research-led model can support substantial long-term value creation if investigational programs achieve clinical and regulatory success.
Fabry Asset Monetization
Selling ST-920 to PTC converted a major pipeline asset into substantial immediate cash while retaining potential milestone upside. Although proceeds are subject to bankruptcy priorities, the transaction demonstrates that parts of Sangamo’s technology portfolio retain strategic value.
Strong Gross Margin
The high gross margin indicates that Sangamo’s underlying partnered and development-related activities can generate meaningful contribution after direct costs. If revenue-bearing programs return, this gross-profit structure could provide operating leverage, even though current expenses remain too high.
Bears Say
Chapter 11 Restructuring
Chapter 11 places the business under court-supervised restructuring and creates substantial uncertainty around asset ownership, capital allocation, and the company’s future operating structure. Delisting further reduces institutional access and signals that equity holders face an unusually weak position.
Persistent Cash Burn
Sustained operating and free-cash-flow deficits show that the business has not funded itself through operations and continues to consume capital. This weak cash-generation profile limits investment capacity and increases dependence on asset sales, financing, or restructuring outcomes.
Declining Revenue And Negative Equity
Falling revenue reduces the scale available to absorb Sangamo’s cost base, while negative equity reflects a materially weakened financial position. Together, these conditions constrain strategic flexibility and heighten the risk that future value is directed toward creditors or new capital providers.
Sangamo Therapeutics News
SGMOQ FAQ
What was Sangamo Therapeutics’s price range in the past 12 months?
What is Sangamo Therapeutics’s market cap?
When is Sangamo Therapeutics’s upcoming earnings report date?
How were Sangamo Therapeutics’s earnings last quarter?
Is Sangamo Therapeutics overvalued?
Does Sangamo Therapeutics pay dividends?
What is Sangamo Therapeutics’s EPS estimate?
How many shares outstanding does Sangamo Therapeutics have?
What happened to Sangamo Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Sangamo Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Sangamo Therapeutics Stock Smart Score
Company Description
Sangamo Therapeutics
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; small fiber neuropathy for chronic neuropathic pain, and prion disease; Phase 1/2 clinical trial to evaluate the safety and tolerability of the investigational genetically modified cell therapy TX200 in patients undergoing a kidney transplant.; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; giroctocogene fitelparvovec, a Phase 3 study to evaluate the clinical efficacy and safety of giroctocogene fitelparvovec gene therapy in adult male with moderately severe or severe hemophilia A. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Genentech, Inc.; Astellas Gene Therapies, Inc.; Capsid Delivery License Agreement with Eli Lilly and Company; Alexion Pharmaceuticals, Inc. ALS and Frontotemporal Lobar Degeneration; Takeda Huntington's Disease; and other areas, such as plant agriculture and research reagents, including the production of transgenic animals and cell-line engineering with Corteva AgriScience and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California. On June 23, 2026, Sangamo Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Alexander D. Macrae
- Employees
- 142
- Website
- www.sangamo.com
- Address
- 501 Canal Blvd, Richmond, CA, 94804, US
Sangamo Therapeutics (SGMOQ) Earnings & Revenues
SGMOQ Earnings Call
Earnings Call SentimentNeutral
The call highlights meaningful clinical and regulatory progress for ST-920 (rolling BLA, FDA affirmation of 2-year confirmatory endpoint, durable long-term patient data) and continued advancement across neurology programs and platform technologies. However, material near-term risks center on capital availability and a NASDAQ delisting determination that forced a transition to the OTCQB market. Progress on regulatory and scientific fronts is balanced by significant financing and market-listing challenges that could impact execution and timing.
View all SGMOQ earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 3 | 10 |
| Technical Analysis | 1 | 3 | 5 |
| Moving Averages | 7 | 0 | 5 |










